BridgeBio CEO and leadership

Brian Stephenson is a CFO at BRIDGEBIO PHARMA INC..

Cameron Turtle, Ph.D. has served as our Chief Strategy Officer since January 2021. Prior to that, he served as our Senior Vice President, Portfolio Management and Corporate Development, from January 2018 until December 2020 and served as a Director, Portfolio Management, from February 2017 to December 2017. Dr. Turtle has also worked for our subsidiary, Eidos Therapeutics, since February 2017, as the chief business officer, and currently serves as a director of certain of our subsidiaries, including Aspa Therapeutics, since June 2018, CoA Therapeutics, Inc. since January 2018, Dermecular since July 2017 and Fortify Therapeutics since December 2017. Dr. Turtle previously worked as vice president of business development and operations for our subsidiary, Navire Pharmaceuticals, Inc., from February 2017 to March 2018. From August 2016 to January 2017, Dr. Turtle was a consultant at McKinsey & Company. Dr. Turtle received his B.S. with honors in bioengineering from the University of Washington and his D. Phil. in cardiovascular medicine from University of Oxford, St. John’s College, where he was a Rhodes Scholar.

Brian Stephenson is a CFO at BRIDGEBIO PHARMA INC..

Cameron Turtle, Ph.D. has served as our Chief Strategy Officer since January 2021. Prior to that, he served as our Senior Vice President, Portfolio Management and Corporate Development, from January 2018 until December 2020 and served as a Director, Portfolio Management, from February 2017 to December 2017. Dr. Turtle has also worked for our subsidiary, Eidos Therapeutics, since February 2017, as the chief business officer, and currently serves as a director of certain of our subsidiaries, including Aspa Therapeutics, since June 2018, CoA Therapeutics, Inc. since January 2018, Dermecular since July 2017 and Fortify Therapeutics since December 2017. Dr. Turtle previously worked as vice president of business development and operations for our subsidiary, Navire Pharmaceuticals, Inc., from February 2017 to March 2018. From August 2016 to January 2017, Dr. Turtle was a consultant at McKinsey & Company. Dr. Turtle received his B.S. with honors in bioengineering from the University of Washington and his D. Phil. in cardiovascular medicine from University of Oxford, St. John’s College, where he was a Rhodes Scholar.

Michael joined BridgeBio to bring genetically targeted treatments to those patients with the highest unmet need. He is responsible for identifying and acquiring new technologies and playing a role in both the parent and subsidiary companies. Michael is the CEO of QED Therapeutics and has overseen the creation of 17 companies. He is a voting board member for 5 of BridgeBio’s subsidiary companies and cofounded PellePharm, one of BridgeBio’s portfolio companies, while in medical school. Prior to BridgeBio, Michael consulted for McKinsey & Company’s Silicon Valley Office where he served biotech clients across the US and EU. He received his BA from Harvard University and holds an MD from Stanford University. Originally from Oklahoma, he is a die-hard fan of the Oklahoma Sooners and a sworn enemy of any football team that opposes them.